Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

NCT06374459 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

152

Enrollment

OTHER

Sponsor class

Conditions

Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer

Interventions

DRUG: Zumsemetinib
DRUG: Capecitabine
DRUG: Zoledronic acid
DRUG: Denosumab

Sponsor

Washington University School of Medicine

Collaborators

[object Object]
[object Object]